|
KMID : 0942820050040010021
|
|
Journal of Korean Brain Tumor Society
2005 Volume.4 No. 1 p.21 ~ p.25
|
|
|
Clinical Efficacy and Toxicity of Concurrent Chemoradiotherapy in Patients with Malignant Glioma
|
|
Lim Dong-Hwan
Jeun Sin-Soo
Park Chun-Kun
Kang Joon-Ki
Kim Moon-Chan
Hong Yong-Kil
|
|
|
Abstract
|
|
|
Objective: Concurrent chemotherapy and radiotherapy trials have been reported to increase anti-tumoral effect and toxicity in several solid cancers, but little has been known in brain tumors. We analyzed clinical efficacy and toxicity of the concurrent therapy as a first line modality in malignant glioma patients.
Methods: From March 1998 to December 2003, twenty- five patients were enrolled in this study. They are composed of 11 glioblastomas(GBM), 8 anaplastic astrocytomas(AA), 5 anaplastic oligodendrogliomas(AO), and 1 anaplastic oligoastrocytoma(AOA). Mean age was 45.3(19-67) years old with 14 females and 11 males. Both radiotherapy and chemotherapy, composed of BCNU(120mg/m2) or CCNU(75-110mg/m2), procarbazine(60mg/m2) and vincristine(1.4
mg/m2), started simultaneously within 2 weeks after surgery.
Results: Median progression-free survival time(PFS) was 9 months for the patients with GBM, and 19 months for the patients with Non-GBM. Grade III/IV leukopenia developed in 7 of 25(28%) patients and thrombocytopenia in 2 of 25 (8%). Radiation necrosis occurred in 3 patients(12%).
Conclusion: Concurrent chemoradiotherapy improved PFS in high-grade glioma patients and its toxicity was tolerable. These preliminary results suggest that further studies would be warranted to improve the clinical efficacy of this therapy in malignant gliomas.
|
|
|
KEYWORD
|
|
|
Glioma, Concurrent chemoradiotherapy, Radiation necrosis, Toxicity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|